These findings suggest that CML treatment upregulates the RAGE/ERK/NFкB signals while concurrently downregulating the activation of AKT and GSK3α/β in osteosarcoma cells. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.